Twitter Thread by Intrinsic Compounding





When in doubt, read the business again and revisit your thesis notes (checklist in my case)

Sameer Hiremath:

Yes, so CDMO currently our split is about 50:50 between CDMO and generic APIs, but with this whole China+1 and this COVID happening there is a lot of new projects coming like the ten-year contract, we just signed, we have several other projects in discussion so the animal health vertical itself will grow, the human health CDMO will also tremendously grow and the growth is getting accelerated and the margins of the business are better in the CDMO compared to the generic API space, so we are working on that and we expect the numbers to look very healthy and growth to be pretty strong in the CDMO space over the next two, three, four years.